Tetraphase Pharmaceuticals, Inc. (TTPH): Price and Financial Metrics

Tetraphase Pharmaceuticals, Inc. (TTPH): $2.20

0.08 (-3.51%)

POWR Rating

Component Grades








Add TTPH to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

TTPH Price/Volume Stats

Current price $2.20 52-week high $8.60
Prev. close $2.28 52-week low $0.56
Day low $2.18 Volume 282,600
Day high $2.27 Avg. volume 932,542
50-day MA $2.42 Dividend yield N/A
200-day MA $2.32 Market Cap 15.98M

TTPH Stock Price Chart Interactive Chart >

Tetraphase Pharmaceuticals, Inc. (TTPH) Company Bio

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create antibiotics for serious and life-threatening MDR bacterial infections. The company was founded in 2006 and is based in Watertown, Massachusetts.

TTPH Latest News Stream

Event/Time News Detail
Loading, please wait...

TTPH Latest Social Stream

Loading social stream, please wait...

View Full TTPH Social Stream

Latest TTPH News From Around the Web

Below are the latest news stories about Tetraphase Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTPH as an investment opportunity.

The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy

The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc...

Yahoo | June 25, 2020

La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…

GlobeNewswire | June 24, 2020

La Jolla Pharma makes unsolicited bid for Tetraphase Pharma

The bidding competition for Tetraphase Pharmaceuticals (TTPH) is not over yet. La Jolla Pharmaceutical (LJPC) has submitted an unsolicited bid of $43.0M in cash plus an additional $16.0 payable under contingent value rights (CVRs).The board has determined that the offer is superior to Melinta Therapeutics' (MLNT) bid of $39.0M in...

Seeking Alpha | June 22, 2020

La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer

The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com

Benzinga | June 22, 2020

Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company ("La Jolla") to acquire Tetraphase for $43.0 million in cash, plus an additional aggregate amount of $16.0 million in cash potentially payable under contingent value rights ("CVRs") to be issued in the transaction (the "La Jolla Proposal"), and that on June 21, 2020 the Board determined that the La Jolla Proposal is a "Superior Offer" under the terms of the Agreement and Plan of Merger, dated June 4, 2020, t...

Yahoo | June 22, 2020

Read More 'TTPH' Stories Here

TTPH Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -89.62%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -87.57%

Continue Researching TTPH

Here are a few links from around the web to help you further your research on Tetraphase Pharmaceuticals Inc's stock as an investment opportunity:

Tetraphase Pharmaceuticals Inc (TTPH) Stock Price | Nasdaq
Tetraphase Pharmaceuticals Inc (TTPH) Stock Quote, History and News - Yahoo Finance
Tetraphase Pharmaceuticals Inc (TTPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!